DocDollars

Endo Pharmaceuticals Inc.

PA · United States · Reporting entity ID 100000000285

Total reported 2019–2025
$48.0M
#180 of 2,960 reporting companies — 0.1% of all reported industry payments
$10.4M in general payments across 85,870 records, plus $37.7M in research funding across 4,162 records.

How it breaks down

General payments $10,351,347
Research funding $37,694,129

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Endo Pharmaceuticals Inc. reported $48.0M to US doctors and teaching hospitals from 2019 to 2025, ranking #180 of 2,960 reporting companies. 78% of that was research funding and 22% general payments such as consulting, speaking, food and travel. 85,870 general payment records and 4,162 research records were filed.

Common questions about Endo Pharmaceuticals Inc.

How much has Endo Pharmaceuticals Inc. paid US doctors?

Endo Pharmaceuticals Inc. reported $48,045,476 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $10,351,347 in general payments, $37,694,129 in research funding.

How does Endo Pharmaceuticals Inc. rank among drug and device companies?

It ranks #180 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Endo Pharmaceuticals Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.